This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Big Pharma teeters on the edge of a patent cliff that could strip away $300 billion — a sixth of the industry’s overall revenue — by 2030, according to an Evaluate report. The high-altitude, high-stakes test will determine which companies are nimble enough to keep their footing. Not all major pharma companies face the same exposure. Some, like Eli Lilly and Novo Nor ...